Natera Stock News

CareDx (CDNA) announced that the Company won its false advertising case against Natera (NTRA) as a jury found that Natera and its senior executives intentionally and recklessly misled…

Natera (NTRA) said it had enrolled 1,000 patients in over 100 sites across the U.S. in its BESPOKE CRC clinical study to measure the impact of its serial test Signatera in…

LOS ANGELES--(BUSINESS WIRE)---- $NTRA #NTRA--The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm

Gainers CEA Industries Inc. (NASDAQ: CEAD ) shares surged 33.4% to $2.7350 after the company reported it signed a $2.1 million contract. Yield10 Bioscience, Inc. (NASDAQ: YTEN ) shares jumped 29% to $5.98 following better-than-expected Q4 results. Ebix, Inc. (NASDAQ: EBIX ) gained 25.4% to $39.90. The company recently posted upbeat quarterly sales. Pintec Technology Holdings Limited (NASDAQ: PT ) jumped 25.4% to $0.5984 after jumping around 14% on Wednesday. Enservco Corporation (NYSE: ENSV ) shares gained 23.7% to $3.7358 after dropping 28% on Wednesday. Natera, Inc. (NASDAQ: NTRA ) jumped 21.9% to $44.87. Shares closed down more than 30% Wednesday. The company responded and said it disagreed with the accuracy of the report. Analysts at Canaccord and Piper defended the stock. Eco Wave Power Global AB (NASDAQ: WAVE ) rose 20.4% to $6.02 following a 15% decline on Wednesday. Indonesia Energy Corporation Limited (NYSE: INDO ) gained 18.9% to $40.00. The company announced that it commenced drilling of two back-to-back production wells at the Kruh block.

Kala Pharmaceuticals KALA +20%. Natera NTRA +17%. Sunshine Biopharma SBFM -32%. Myomo (MYO) -28%.

Natera Inc. (NTRA) shares rose 14%, paring almost half of the 33% decline on Wednesday, following a short report from Hindenburg Research on the diagnostics testing…

NTRA stock is flying higher after the company addressed Hindenburg's short report. Wall Street analysts are on Natera's side as well.

A whale with a lot of money to spend has taken a noticeably bearish stance on Natera . Looking at options history for Natera (NASDAQ: NTRA ) we detected 39 strange trades. If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 69% with bearish. From the overall spotted trades, 15 are puts, for a total amount of $3,241,890 and 24, calls, for a total amount of $1,339,258. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $65.0 for Natera over the last 3 months. Volume & Open Interest Development In terms of liquidity … Full story available on Benzinga.com

Natera Inc (NASDAQ: NTRA ) shares are trading lower by 31.2% at $37.66 after Hindenburg Research issued a short report on the stock. Hindenburg Research stated , "Based on more than 2 dozen interviews with former Natera employees, patients and industry experts, a review of hundreds of online complaints, FOIA requests to state Medicaid offices and … Full story available on Benzinga.com

Shares of Natera Inc. plummeted 32.9% in active afternoon trading Wednesday toward a 22-month low, enough to pace all of the Nasdaq''s decliners, after noted short seller Hindenburg Research called the Texas-based genetic testing services company, "Pioneers in deceptive medical billing." Trading volume ballooned to 33.9 million shares, compared with the full-day average of less than 1 million shares. "Based on more than 2 dozen interviews with former Natera employees, patients and industry experts, a review of hundreds of online complaints, FOIA requests to state Medicaid offices and state Attorneys General, and the company''s financial filings, we show how Natera''s revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers," Hindenburg''s report said. Natera responded to what it called the "misleading" report: "We disagree with the accuracy of this report which was generated in an attempt to make a quick profit by short sellers Hindenburg Research, who are currently under criminal investigation by the Department of Justice for illegal trading tactics." Although the stock pared intraday losses of as much as 52.3%, the selloff shaved about $1.72 billion off the company''s market capitalization, bringing it down to about $3.52 billion.

By Sam Boughedda Investing.com — Clinical genetic testing company Natera Inc (NASDAQ:) is down 48% after Hindenburg Research released a short report on the company titled “Natera: Pioneers In Deceptive Medical Billing.” The activist short-selling research firm said that after various interviews with former employees, patients, and industry experts, as well as reviews of online complaints …

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On January 1, 2022, an article from the New York Times called into question the accuracy of certain prenatal tests, alleging that positive results on tests are incorrect about 85 p

Natera Inc (NASDAQ: NTRA) analyst Kyle Mikson of Canaccord Genuity Capital reiterated a Buy rating Wednesday on the genetic testing company  following a Hindenburg Research short report rele